PHARMACOKINETIC ASSESSMENT OF REVUMENIB IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE LEUKEMIAS HARBORING A KMT2A REARRANGEMENT OR NPM1 MUTATION: IMPACT OF FOOD AND CONCOMITANT MEDICATIONS (EHA 2026) - May 12, 2026 - Abstract #EHA-2228; PF564; Pres time: Jun 12, 2026; 06:45 PM - 07:45 PM; Location: Hall A; P1/2 | "Co ‑ administration with strong CYP3A4i (eg, voriconazole, posaconazole, itraconazole) resulted in ~2 ‑ fold increase in revumenib C max and AUC, whereas moderate CYP3A4i (eg, fluconazole, isavuconazole) had no meaningful effect. Reused with permission. This abstract was accepted and previously presented at the 2026 ASCO Annual Meeting."
Clinical • PK/PD data • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • KMT2A • NPM1 • NUP98
|
|
Enoch Cobbina 1; Joshua Stewart 1; Yuwei Lin 2; Angela Smith 1; Ophelia Yin 1; Ghayas Issa3
|